MICRODOSING FOR EARLY BIOKINETIC STUDIES IN HUMANS.
(2010) In Radiation Protection Dosimetry 139. p.348-352- Abstract
- Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-would mean that new drugs can be tested earlier in humans than done today. The human microdosing concept-or 'Phase 0'-may offer improved candidate selection, reduced failure rates in the drug development line and a reduction in the use of laboratory animals in early drug development, factors which will help to speed up drug development and also reduce the costs. Microdosing utilises sub-pharmacological amounts of the substance to open opportunities for early studies in man. Three technologies are used for microdosing: accelerator mass spectrometry (AMS), positron emission tomography and liquid chromatography-tandem mass spectrometry. This... (More)
- Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-would mean that new drugs can be tested earlier in humans than done today. The human microdosing concept-or 'Phase 0'-may offer improved candidate selection, reduced failure rates in the drug development line and a reduction in the use of laboratory animals in early drug development, factors which will help to speed up drug development and also reduce the costs. Microdosing utilises sub-pharmacological amounts of the substance to open opportunities for early studies in man. Three technologies are used for microdosing: accelerator mass spectrometry (AMS), positron emission tomography and liquid chromatography-tandem mass spectrometry. This paper focuses on the principle of AMS and discusses the current status of microdosing with AMS. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1552518
- author
- Stenström, Kristina LU ; Sydoff, Marie LU and Mattsson, Sören LU
- organization
- publishing date
- 2010
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Radiation Protection Dosimetry
- volume
- 139
- pages
- 348 - 352
- publisher
- Oxford University Press
- external identifiers
-
- wos:000277738200066
- pmid:20167793
- scopus:77953353160
- pmid:20167793
- ISSN
- 1742-3406
- DOI
- 10.1093/rpd/ncq029
- language
- English
- LU publication?
- yes
- id
- cf642926-7863-4588-a78c-0a03455c3a83 (old id 1552518)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20167793?dopt=Abstract
- date added to LUP
- 2016-04-04 09:05:15
- date last changed
- 2022-01-29 08:12:02
@article{cf642926-7863-4588-a78c-0a03455c3a83, abstract = {{Microdosing is a new concept in drug development that-if implemented in the pharmaceutical industry-would mean that new drugs can be tested earlier in humans than done today. The human microdosing concept-or 'Phase 0'-may offer improved candidate selection, reduced failure rates in the drug development line and a reduction in the use of laboratory animals in early drug development, factors which will help to speed up drug development and also reduce the costs. Microdosing utilises sub-pharmacological amounts of the substance to open opportunities for early studies in man. Three technologies are used for microdosing: accelerator mass spectrometry (AMS), positron emission tomography and liquid chromatography-tandem mass spectrometry. This paper focuses on the principle of AMS and discusses the current status of microdosing with AMS.}}, author = {{Stenström, Kristina and Sydoff, Marie and Mattsson, Sören}}, issn = {{1742-3406}}, language = {{eng}}, pages = {{348--352}}, publisher = {{Oxford University Press}}, series = {{Radiation Protection Dosimetry}}, title = {{MICRODOSING FOR EARLY BIOKINETIC STUDIES IN HUMANS.}}, url = {{http://dx.doi.org/10.1093/rpd/ncq029}}, doi = {{10.1093/rpd/ncq029}}, volume = {{139}}, year = {{2010}}, }